Stifel Nicolaus Starts Halozyme Therapeutics (HALO) at Buy
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.74 +0.98%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 28
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 28
Join SI Premium – FREE
Stifel Nicolaus initiates coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Buy. PT $10.
For more ratings news on Halozyme Therapeutics click here and for the rating history of Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.71 yesterday.
For more ratings news on Halozyme Therapeutics click here and for the rating history of Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Stifel Reiterates Hold Rating on The Campbell's Co. (CPB)
- Morgan Stanley Resumes Deutsche Boerse AG (DB1:GR) (DBOEY) at Equalweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
